De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study-Reference-Cited by-同舟云学术

De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

Published:2019-06 Issue:6 Volume:30 Page:921-926
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Guarneri V.,Dieci M.V.^ORCID,Bisagni G.,Frassoldati A.,Bianchi G.V.,De Salvo G.L.,Orvieto E.,Urso L.,Pascual T.,Paré L.,Galván P.,Ambroggi M.,Giorgi C.A.,Moretti G.,Griguolo G.^ORCID,Vicini R.,Prat A.,Conte P.F.^ORCID

Funder

Italian Ministry of Health

Instituto de Salud Carlos III

Plan Estatal de Investigacion Cientifica

Banco Bilbao Vizcaya Argentaria Foundation

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/30/6/921/28871778/mdz055.pdf

Reference19 articles.

1. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis;Cortazar;Lancet,2014

2. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial;Baselga;Lancet,2012

3. Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study;Guarneri;J Clin Oncol,2012

4. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial;Gianni;Lancet Oncol,2012

5. Therapeutic implications of estrogen receptor signaling in HER2-positive breast cancers;Nahta;Breast Cancer Res Treat,2012

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance;Nature Reviews Clinical Oncology;2024-09-13

2. Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain;Nature Reviews Clinical Oncology;2024-05-22

3. A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple‐positive breast cancer;MedComm;2024-03

4. Clinicopathological characteristics, treatment patterns and out-comes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study;2024-01-08

5. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer;Breast Cancer Research;2024-01-03